证券代码：688356 证券简称：键凯科技 公告编号：2025-041 北京键凯科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 1、 公司在任董事9人，出席9人； 2、 董事会秘书陈斌先生出席本次会议，其他高级管理人员列席了本次会议。 | 1、出席会议的股东和代理人人数 | 26 | | --- | --- | | 普通股股东人数 | 26 | | 2、出席会议的股东所持有的表决权数量 | 19,373,852 | | 普通股股东所持有表决权数量 | 19,373,852 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 32.0214 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 32.0214 | 注：截至本次股东会股权登记日，公司回购专用证券账户中股份数为 147,914 股，该等回 购股份不享有股东会表决权。 （四） 表决方式是否符合《公司法》及公司章程的规 ...

北京市时代九和律师事务所 关于北京键凯科技股份有限公司 2025 年第二次临时股东会的 法律意见书 二〇二五年十一月 2025 年第二次临时股东会的 法律意见书 致：北京键凯科技股份有限公司 北京市时代九和律师事务所（以下简称"本所"）接受北京键凯科技股份有 限公司（以下简称"公司"）委托，指派陆群威律师和谢淮桉律师列席了公司 2025 年第二次临时股东会（以下简称"本次股东会"），就本次股东会的相关事项进行 见证，并出具法律意见书。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）等相关法律法规、规范性文件以及《北京键凯科技股份 有限公司章程》（以下简称"《公司章程》"）的规定出具。 为出具本法律意见书，本所律师审查了公司提供的与本次股东会有关的文件、 资料及相关材料。本所律师出具本法律意见书基于公司向本所律师提供的一切原 始文件、副本材料均真实、准确、完整、有效，不存在虚假记载、误导性陈述或 者重大遗漏，有关文件的印章和签字均真实、有效，有关副本、复印件等材料均 与正本或原始材料 ...

Core Viewpoint - The announcement details the results of a share transfer by XUAN ZHAO, the controlling shareholder of Beijing JianKai Technology Co., Ltd, involving the transfer of 1,819,521 shares at a price of 76.18 yuan per share, which will reduce his shareholding from 24.56% to 21.56% [2][3][6]. Group 1: Transfer Details - The share transfer price is set at 76.18 yuan per share, with a total of 1,819,521 shares being transferred [2]. - The transfer will not result in a change of control for the company, as XUAN ZHAO and his concerted parties will still hold a significant portion of shares [3][7]. - The transfer process involved 194 institutional investors receiving the subscription invitation, with 27 valid bids submitted during the specified time [6][7]. Group 2: Shareholder Information - XUAN ZHAO is identified as the controlling shareholder, actual controller, chairman, and general manager of the company, holding more than 5% of the shares prior to the transfer [4]. - XUAN ZHAO and LIHONG GUO are recognized as concerted parties due to their marital relationship, although LIHONG GUO did not participate in this transfer [4]. Group 3: Compliance and Regulation - The share transfer process adhered to principles of fairness and compliance with relevant securities market regulations, including the Company Law and Securities Law of the People's Republic of China [8].

Core Viewpoint - On November 17, 19 A-share listed companies disclosed shareholding reductions, while Huangtai Liquor Industry announced a plan for share repurchase ranging from 70 million to 140 million yuan [1][2]. Group 1: Shareholding Increases - Huangtai Liquor Industry's controlling shareholder plans to increase its stake in the company by 70 million to 140 million yuan [2]. Group 2: Shareholding Reductions - Fubon Technology's specific shareholder, Zhenghong Development, intends to reduce its stake by no more than 0.59% [2]. - Huijie Co., Ltd.'s shareholder Lin Shengzhi plans to reduce his stake by no more than 2% [2]. - Chengdu Huamei's shareholders plan to reduce their stakes [2]. - Dexin Technology's shareholder Xinjiang Guotou plans to reduce by no more than 1% [2]. - Gokai Technology's major shareholder plans to reduce by no more than 0.7% [2]. - Fulin Precision's second-largest shareholder, An Zhifu, plans to reduce by no more than 1% [2]. - Zhouming Technology's controlling shareholder Lin Zhaofeng plans to reduce by no more than 1.99% [2]. - Keheng Co., Ltd.'s shareholder Wang Guojiang plans to reduce by no more than 2% [2]. - Yijiahe's shareholder Zhejiang Junhong plans to reduce by no more than 2% [2]. - Tianqi Co., Ltd.'s director Shen Baowei plans to reduce by no more than 0.0631% [2]. - Jiankai Technology's controlling shareholder is transferring 1.8195 million shares [2]. - Huizhiwei's shareholder GZPA plans to reduce by no more than 2.25% [2]. - Xingli Food's shareholder Shanghai Houxu plans to reduce by no more than 3% [2]. - Tiejie Technology's largest shareholder Alibaba Network reduced its stake by 4.2392 million shares from November 6 to November 17 [2]. - Shengke Communication's second-largest shareholder, the National Fund, reduced its stake by 10.1891 million shares from August 25 to November 17 [2]. - Yayi International's shareholder Zhongnong Group plans to reduce by no more than 1% [2]. - Yatai Co., Ltd.'s controlling shareholder Yatai Group plans to reduce by no more than 1% [2]. - Guangge Technology's shareholders, Jishi Chuangtou and Fangguang No. 2, plan to reduce their stakes by no more than 3.99% [2]. - Kaichuang International's Xiaojian Technology and its concerted actions reduced their stakes by 2.9321 million shares from November 7 to November 17 [2].

证券代码：688356 证券简称：键凯科技 公告编号：2025-039 北京键凯科技股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动 触及 1%整数倍的提示性公告 XUAN ZHAO（以下简称"转让方"）保证向北京键凯科技股份有限公司（以下简 称"键凯科技"或"公司"）提供的信息内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 一、 转让方情况 (一)转让方基本情况 截至 2025 年 11 月 11 日，转让方所持首发前股份的数量、占键凯科技总股本 比例情况如下： | | | 本次询价转让的价格为76.18元/股，转让的股票数量为1,819,521股。 公司控股股东、实际控制人、董事长、总经理 XUAN ZHAO参与本次询价转 让。 本次转让不会导致公司控股股东、实际控制人发生变化。 本次权益变动后，XUAN ZHAO 及其一致行动人合计持有上市公司股份比例 将从 24.56%减少至 21.56%，持有公司权益比例变动触及 1%的整数倍。 | | | 本次询价转 ...

中信建投证券股份有限公司 关于北京键凯科技股份有限公司 股东向特定机构投资者询价转让股份的核查报告 上海证券交易所： 中信建投证券股份有限公司（以下简称"中信建投证券"或"组织券商"） 受委托担任 XUAN ZHAO（以下简称"出让方"）以向特定机构投资者询价转 让（以下简称"询价转让"）方式减持所持有的北京键凯科技股份有限公司 （以下简称"公司"或"键凯科技"）首次公开发行前已发行股份的组织券商。 经核查，组织券商就本次询价转让的股东、受让方是否符合《上海证券交 易所科创板上市公司自律监管指引第 4 号——询价转让和配售（2025 年 3 月修 订）》（以下简称"《询价转让和配售指引》"）要求，本次询价转让的询价、 转让过程与结果是否公平、公正，是否符合《询价转让和配售指引》的规定作 出如下报告说明。 一、本次询价转让概况 （一）本次询价转让出让方 截至 2025 年 11 月 11 日，出让方所持公司股份的数量、占公司总股本比例 情况如下： | 序号 | 股东名称 | 持股数量（股） | 持股占总股本比例 | | --- | --- | --- | --- | | 1 | XUAN ZHAO | 14,8 ...

键凯科技公告，董事长XUAN ZHAO参与本次询价转让，转让价格为76.18元/股，转让数量为181.95万 股，占总股本的3.00%。本次转让后，XUAN ZHAO及其一致行动人合计持有上市公司股份比例将从 24.56%减少至21.56%，持有公司权益比例变动触及1%的整数倍。 ...

Core Viewpoint - JianKai Technology's stock price has experienced fluctuations, with a year-to-date increase of 54.36% but a recent decline in the last five trading days by 5.13% [2] Group 1: Stock Performance - As of November 13, JianKai Technology's stock price was 87.66 CNY per share, with a market capitalization of 5.317 billion CNY [1] - The stock has seen a net outflow of 4.8918 million CNY in principal funds, with large orders buying 2.3557 million CNY (4.87%) and selling 7.2475 million CNY (14.99%) [1] - Year-to-date, the stock has been on the龙虎榜 once, with a net purchase of 39.1731 million CNY on July 21 [2] Group 2: Financial Performance - For the period from January to September 2025, JianKai Technology reported revenue of 211 million CNY, a year-on-year increase of 13.47%, and a net profit attributable to shareholders of 40.7246 million CNY, up 24.72% [2] - The company has distributed a total of 178 million CNY in dividends since its A-share listing, with 99.8755 million CNY distributed in the last three years [3] Group 3: Company Overview - JianKai Technology, established on October 9, 2001, and listed on August 26, 2020, is located in Beijing and specializes in the research, production, and sales of medical-grade polyethylene glycol and its active derivatives [2] - The company's main revenue sources are product sales (96.79%), technology usage fees (2.91%), and transportation services (0.30%) [2] - The company operates within the pharmaceutical and biotechnology sector, focusing on chemical pharmaceuticals and raw materials, with concepts including anti-cancer drugs and medical devices [2]

重要内容提示： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688356 证券简称：键凯科技 公告编号：2025-038 北京键凯科技股份有限公司 股东询价转让定价情况提示性公告 XUAN ZHAO保证向北京键凯科技股份有限公司（以下简称"公司"）提供的信息内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 ● 根据2025年11月12日询价申购情况，初步确定的本次询价转让价格为76.18元/股。 ● 受让方通过询价转让受让的股份，在受让后6个月内不得转让。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为76.18元/股。 （二）参与本次询价转让报价的机构投资者家数为17家，涵盖了基金管理公司、保险公司、证券公司、 私募基金管理人、合格境外投资者等专业机构投资者。参与本次询价转让报价的机构投资者合计有效认 购股份数量为3,308,000股，对应的有效认购倍数为1.82倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为12家机构投资者，拟受让 ...

Group 1 - The "Bohai Beautiful Bay" Industrial Innovation Development Conference was successfully held in Tianjin Economic Development Zone, marking the establishment of the Bohai Beautiful Bay Industrial Development Promotion Center, which aims to enhance the beauty industry and support high-quality development [1] - Key projects were signed during the conference, including a collaboration between JianKai Technology and Tianjin Economic Development Zone to build a medical beauty industrialization base, indicating a strategic expansion in the medical beauty sector [1][2] - JianKai Technology has been focusing on the PEG and its derivatives industry since its establishment, and is one of the few companies in China capable of producing high-purity and low-dispersity pharmaceutical-grade PEG [2] Group 2 - JianKai Technology's first medical beauty product, JK-2122H (PEG cross-linked hyaluronic acid), is expected to contribute to sales revenue in 2025, being the first domestic filler using PEG as a cross-linking agent, which offers better biocompatibility and safety [2] - The second medical beauty product, JK-1136H (water needle), has also received acceptance for its market application, which will further enrich the company's product matrix and provide new growth opportunities [2] - The collaboration within the "Bohai Beautiful Bay" initiative is expected to create a cluster of beauty and medical beauty industries, enhancing the competitive edge of JianKai Technology and driving significant growth in the high-end medical beauty market [3]